Progress towards elimination goals for viral hepatitis.
Journal
Nature reviews. Gastroenterology & hepatology
ISSN: 1759-5053
Titre abrégé: Nat Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101500079
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
accepted:
09
06
2020
pubmed:
25
7
2020
medline:
6
11
2020
entrez:
25
7
2020
Statut:
ppublish
Résumé
The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top four global infectious diseases. In 2016, the 194 Member States of the World Health Organization committed to eliminating viral hepatitis as a public health threat by 2030, with a particular focus on hepatitis B virus and hepatitis C virus infection. With only 10 years to go until the 2030 deadline is reached, and although much progress has been made towards elimination, there are still some important gaps in terms of policy and progress. In this Viewpoint, we asked a selection of scientists and clinicians working in the viral hepatitis field for their opinions on whether elimination of viral hepatitis by 2030 is feasible, what the key areas of progress are and what the focus for the next 10 years and beyond should be for viral hepatitis elimination.
Identifiants
pubmed: 32704164
doi: 10.1038/s41575-020-0332-6
pii: 10.1038/s41575-020-0332-6
pmc: PMC7376316
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
533-542Subventions
Organisme : Medical Research Council
ID : MR/R011117/1
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U19 AI088791
Pays : United States
Références
Thomas, D. L. Global elimination of chronic hepatitis. N. Engl. J. Med. 380, 2041–2050 (2019).
pubmed: 31116920
Stanaway, J. D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388, 1081–1088 (2016).
pubmed: 27394647
pmcid: 5100695
Liu, J., Liang, W., Jinga, W. & Liu, M. Countdown to 2030: eliminating hepatitis B disease, China. Bull. World Health Organ. 97, 230–238 (2019).
pubmed: 30992636
pmcid: 6453311
McCulloch, F., Romero, N., MacLachlan, J., Allard, N. & Cowie, B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology 71, 1170–1181 (2020).
pubmed: 31419332
Razavi-Shearer, D. et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3, 383–403 (2018).
Razavi, H., Sanchez Gonzalez, Y., Yuen, C. & Cornberg, M. Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 40, 522–529 (2020).
pubmed: 31815353
World Health Organization. Combating hepatitis B and C to reach elimination by 2030. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf/jsessionid=CADC5914BBC22D9F5FEBA9B2033892A3?sequence=1 (2016).
Schröeder, S. E. et al. Innovative strategies for the elimination of viral hepatitis at a national level: a country case series. Liver Int. 39, 1818–1836 (2019).
pubmed: 31433902
pmcid: 6790606
Tordrup, D. et al. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016–30. Lancet Glob. Health 7, e1180–e1188 (2019).
pubmed: 31353061
Smith, S. et al. Global progress on the elimination of viral hepatitis as a major public health threat: an analysis of WHO member state responses 2017. JHEP Rep. 1, 81–89 (2019).
pubmed: 32039355
pmcid: 7001559
World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (2016).
Razavi, H. et al. Global timing of hepatitis C virus elimination in high-income countries: an updated analysis [abstract THU365]. Presented at the Digital International Liver Conference, 2020.
Cooke, G. et al. Lancet commission: accelerating the elimination of viral hepatitis. Lancet Gastroenterol. Hepatol. 4, 135–184 (2019).
pubmed: 30647010
Palayew, A. et al. Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C. Lancet Gastroenterol. Hepatol. (in press).
Palayew, A. et al. The Hep-CORE Policy Score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS One (in press).
World Health Organization. Global hepatitis report 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1 (2017).
van Santen, D. K. et al. Measuring hepatitis C virus elimination as a public health threat: beyond global targets. J. Viral Hepat. https://doi.org/10.1111/jvh.13294 (2020).
doi: 10.1111/jvh.13294
pubmed: 32187431
Nayagam, S., Shimakawa, Y. & Lemoine, M. Mother-to-child transmission of hepatitis B: what more needs to be done to eliminate it around the world? J. Viral Hepat. 27, 342–349 (2020).
pubmed: 31698534
World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019: accountability for the global health sector strategies, 2016–2021. https://www.who.int/hiv/strategy2016-2021/progress-report-2019/en/ (2019).
Heffernan, A., Cooke, G. S., Nayagam, S., Thursz, M. & Hallett, T. B. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet 393, 1319–1329 (2019).
pubmed: 30704789
pmcid: 6484702
Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545–558 (2019).
pubmed: 30981686
pmcid: 6732795
Stockdale, A. J. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. https://doi.org/10.1016/j.jhep.2020.04.008 (2020).
doi: 10.1016/j.jhep.2020.04.008
pubmed: 32863046
pmcid: 7438974
Besombes, C. et al. The epidemiology of hepatitis delta virus infection in Cameroon. Gut https://doi.org/10.1136/gutjnl-2019-320027 (2020).
doi: 10.1136/gutjnl-2019-320027
pubmed: 31907297
Fanning, G. C., Zoulim, F., Hou, J. & Bertoletti, A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug. Discov. 18, 827–844 (2019).
pubmed: 31455905
World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). Generalized Cost-Effectiveness Analysis http://www.who.int/choice/cost-effectiveness/generalized/en/ (2017).
World Health Organization. Viral Hepatitis Strategic Information and Modelling Reference Group: meeting report. https://www.who.int/hepatitis/publications/strategic-information-modelling-meeting/en/ (2016).
Waked, I. et al. Screening and treatment program to eliminate hepatitis C in Egypt. N. Engl. J. Med. 382, 1166–1174 (2020).
pubmed: 32187475
Medicines Patent Pool. The Medicines Patent Pool 2018–2022 Strategy. https://medicinespatentpool.org/who-we-are/strategy/ (2018).
World Health Organization. Hepatitis data and statistics in the Western Pacific. https://www.who.int/westernpacific/health-topics/hepatitis/regional-hepatitis-data (2018).
Woodring, J. et al. Progress toward hepatitis B control and elimination of mother-to-child transmission of hepatitis B virus — Western Pacific Region, 2005–2017. MMWR Morb. Mortal. Wkly. Rep. 68, 195–200 (2019).
pubmed: 30817746
pmcid: 6394384
Ioannou, G. N. & Feld, J. What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection? Gastroenterology 156, 446–460.e2 (2019).
pubmed: 30367836
Pawlotsky, J.-M. et al. EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 69, 461–511 (2018).
Lazarus, J. V. et al. Too many people with viral hepatitis are diagnosed late — with dire consequences. Nat. Rev. Gastroenterol. Hepatol. 16, 451–452 (2019).
pubmed: 31320742
Zoulim, F. et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 64, 1824–1833 (2015).
pubmed: 26449729
pmcid: 5993679
Belli, L. S. et al. Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J. Hepatol. 69, 810–817 (2018).
pubmed: 29940268
Terrault, N. A. & Pageaux, G. P. A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over! J. Hepatol. 69, 767–768 (2018).
pubmed: 30104027
Do, A. & Reau, N. S. Chronic viral hepatitis: current management and future directions. Hepatol. Commun. 4, 329–341 (2020).
pubmed: 32140652
pmcid: 7049676
Lee, S. W. et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut https://doi.org/10.1136/gutjnl-2019-318947 (2019).
doi: 10.1136/gutjnl-2019-318947
pubmed: 31822581
pmcid: 7306978
El-Akel, W. et al. National treatment programme of hepatitis C in Egypt: hepatitis C virus model of care. J. Viral Hepat. 24, 262–267 (2017).
pubmed: 28145032
Averhoff, F. et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J. Hepatol. 72, 680–687 (2020).
pubmed: 31811882
GAVI. Annex C: Hepatitis B birth dose investment case. GAVI https://www.gavi.org/sites/default/files/document/ppc-meeting-18-19-october-2018---vis-06a---annex-c--hepatitis-b-birth-dose-investment-casepdf.pdf (2018).
Cornberg, M. et al. Guidance for the design and endpoints of clinical trials in chronic hepatitis B — report from the 2019 EASL-AASLD HBV treatment endpoints conference. Hepatology https://doi.org/10.1002/hep.31030 (2019).
doi: 10.1002/hep.31030
pubmed: 31713892
Chen, D. S. Taiwan commits to eliminating hepatitis C in 2025. Lancet Infect. Dis. 19, 466–467 (2019).
pubmed: 31034387
Wu, G. H., Pwu, R. F. & Chen, S. C. Achieving hepatitis C elimination in Taiwan — overcoming barriers by setting feasible strategies. J. Formos. Med. Assoc. 117, 1044–1045 (2018).
pubmed: 30449458
Wu, G. H., Pwu, R. F., Chen, S. C. & Chen, D. S. Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver Int. https://doi.org/10.1111/liv.14412 (2020).
doi: 10.1111/liv.14412
pubmed: 33277803
pmcid: 7702130
Ni, Y. H. et al. Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan. Clin. Gastroenterol. Hepatol. 14, 1324–1330 (2016).
pubmed: 27155556
Lin, C. L. & Kao, J. H. Perspectives and control of hepatitis B virus infection in Taiwan. J. Formos. Med. Assoc. 114, 901–909 (2015).
pubmed: 26184565
Kao, J. H. Hepatitis B: from control to cure. J. Formos. Med. Assoc. 117, 868–870 (2018).
pubmed: 30201191
Yang, J. F. et al. Viral hepatitis infections in southern Taiwan: a multicenter community-based study. Kaohsiung J. Med. Sci. 26, 461–469 (2010).
pubmed: 20837342
Nayagam, S. et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect. Dis. 16, 1399–1408 (2016).
pubmed: 27638356
Lemoine, M. et al. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in the Gambia: the prevention of liver fibrosis and cancer in Africa (PROLIFICA) study. Lancet Glob. Health 4, e559–e567 (2016).
pubmed: 27443781
Lin, C. L. & Kao, J. H. Review article: novel therapies for hepatitis B virus cure — advances and perspectives. Aliment. Pharmacol. Ther. 44, 213–222 (2016).
pubmed: 27302653
Pedrana, A. et al. Global hepatitis C elimination: an investment framework. Lancet Gastroeneterol. Hepatol. (in press).
Safreed-Harmon, K. et al. The consensus hepatitis C cascade of care: standardized reporting to monitor progress toward elimination. Clin. Infect. Dis. 29, 12 (2019).
Lazarus, J. V. et al. The micro-elimination approach to eliminate hepatitis C: strategic and operational considerations. Semin. Liv Dis. 38, 181–192 (2018).
Lazarus, J. V. et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J. Intern. Med. 286, 503–525 (2019).
pubmed: 31472002
Grebely, J. et al. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. Expert. Rev. Mol. Diagn. 17, 1109–1115 (2017).
pubmed: 29088981
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastro. Hepatol. 3, 383–403 (2018).
Schmelzer, J. et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastro. Hepatol. 5, 374–392 (2020).
Shimakawa, Y. et al. Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from the Gambia. Gut 65, 2007–2016 (2016).
pubmed: 26185161
Hatzakis, A. et al. Securing sustainable funding for viral hepatitis elimination plans. Liver Int. 40, 260–270 (2020).
pubmed: 31808281
Thio, C. et al. Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. Lancet Infect. Dis. 15, 981–985 (2015).
pubmed: 26145195
Cox, A. L. Medicine: global control of hepatitis C virus. Science 349, 790–791 (2015).
pubmed: 26293940
US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01436357 (2019).
Coalition for Global Hepatitis Elimination. The hepatitis prevention, control, and elimination in Mongolia. https://www.globalhep.org/programs/hepatitis-prevention-control-and-elimination-program-mongolia-eleg-buten-mongol-undesniy (2019).
Huang, J. et al. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver Int. 36, 1595–1603 (2016).
pubmed: 27206379
Chen, D. S. Fighting against viral hepatitis: lessons from Taiwan. Hepatology 54, 381–392 (2011).
pubmed: 21721025
Bartenschlager, R. et al. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies. Virus Res. 248, 53–62 (2018).
pubmed: 29477639